News

PharmiWeb6d
Global Primary Sclerosing Cholangitis (PSC) Market Set to Soar to USD 314.26 Million by 2033 | FMI
The global primary sclerosing cholangitis (PSC) market is on an impressive growth trajectory, with forecasts estimating a market valuation of USD 314.26 million by 2033. This robust expansion is ...
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
Zurich (Switzerland), April 28, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today ...
Morningstar6d
GENFIT: positive late-breaking Phase 2 data for elafibranor in Primary Sclerosing Cholangitis (PSC) to be presented by Ipsen at EASL Congress 2025
Similar findings were seen in other biochemical liver ... primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver ...
Morningstar6d
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug’s Impact in Primary Sclerosing Cholangitis and Related Diseases
1 CCL24 blockade alters the proteomic profile of patients with primary sclerosing cholangitis and down-regulates central disease processes, T Snir, R Greenman, R Aricha, I Vaknin, M Frankel ...
manilatimes6d
Chemomab Reports New Positive Clinical Data at EASL 2025 Supporting Nebokitug's Impact in Primary Sclerosing Cholangitis and Related Diseases
Importantly, linear regression analyses found trends between increasing patient exposure to nebokitug and decreasing levels of relevant PSC disease biomarkers, including liver enzyme ... of patients ...